

# Hi Tech Pharmacal Co. Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

<https://marketpublishers.com/r/HF81E1094BCBEN.html>

Date: May 2025

Pages: 50

Price: US\$ 499.00 (Single User License)

ID: HF81E1094BCBEN

## Abstracts

Hi Tech Pharmacal Co. Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Hi Tech Pharmacal Co. Inc. and its competitors. This provides our Clients with a clear understanding of Hi Tech Pharmacal Co. Inc. position in the [Pharmaceuticals and Biotechnology](#) Industry.

The report contains detailed information about Hi Tech Pharmacal Co. Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for Hi Tech Pharmacal Co. Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The Hi Tech Pharmacal Co. Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios

pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes Hi Tech Pharmacal Co. Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Hi Tech Pharmacal Co. Inc. business.

### **About Hi Tech Pharmacal Co. Inc.**

Hi-Tech Pharmacal Co., Inc. operates as a specialty manufacturer and marketer of prescription, over-the-counter, and nutritional products. The company produces a range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care, and other conditions.

#### **Products**

The company develops, manufactures, and markets products in three categories – Generics, Prescription Brands, and Over the Counter (OTC) Brands.

#### **Generic Products**

The company's generic products are primarily prescription items and include oral solutions and suspensions, topical creams, and ointments, as well as nasal sprays. It also manufactures products in its sterile facility capable of producing liquid ophthalmic, otic, and inhalation products. Additionally, its Midlothian Laboratories division sources and markets generic prescription products, which primarily include prescription vitamins. The generic product category also includes an amount of contract manufacturing sales

for both the prescription and OTC markets.

The company's primary generic products include Dorzolamide with Timolol and Dorzolamide (the generic equivalents of Cosopt and Trusopt from Merck); Fluticasone propionate (the generic equivalent of Flonase from GlaxoSmithKline); Acetic Acid with Hydrocortisone (the generic equivalent of Vosol HC from ECR); Sulfamethoxazole with Trimethoprim (the generic equivalent of Bactrim from Roche); and Acyclovir oral suspension (the generic equivalent of Zovirax from GlaxoSmithKline). It has 43 prescription products approved for marketing by the Food and Drug Administration (FDA) and 1 product with tentative approval.

### ECR Pharmaceuticals

The company, through its subsidiary, E. Claiborne Robins Company, Inc. doing business as ECR Pharmaceuticals (ECR Pharmaceuticals or ECR), engages in the development and distribution of branded prescription pharmaceuticals. ECR's products treat various disease states, including cough and cold symptoms, allergies, poison ivy and contact dermatitis, and pain relief. It has purchased the rights to Zolpimist, Zolpidem tartrate oral spray, for the treatment of insomnia.

ECR's primary products include Lodrane 24/Lodrane 24 D, an extended release antihistamine/ antihistamine with decongestant capsule; DexPak TaperPak, an oral corticosteroid tablet available in 13 day, 10 day, and 6 day tapered packages; Bupap, an analgesic tablet; Vosol HC, a treatment for swimmer's ear; and Tropazone, a treatment for dermatitis.

### Health Care Products Division

The Health Care Products Division (HCP) markets a line of OTC branded products that include over-the-counter medications, nutritional products, cosmetics, and medical devices, primarily for people with diabetes. HCP also has various lines that fall outside the diabetes area in pain management and allergy products.

The company markets a line of OTC branded products primarily for people with diabetes, including Diabetic Tussin cough products; DiabetiDerm dermatological and footcare products; Multi-betic multi-vitamins; Mag-Ox magnesium supplement; Choice DM; and DiabetiSweet. The division also sells the Zostrix brand of capsaicin products for pain management of conditions including arthritis and diabetic foot pain. In addition, HCP markets Nasal Ease homeopathic allergy reliever.

## Customers

The company markets its products to chain drug stores, drug wholesalers, managed care purchasing organizations, certain federal government agencies, generic distributors, mass merchandisers, and mail-order pharmacies. Its major customers include McKesson Corporation, Cardinal Health, Inc., AmeriSourceBergen Corporation, CVS, Walgreens, and Wal-Mart.

## Suppliers

The company's primary supplier is Ragactives S.L.U.

## Competition

The company's competitors include Wockhardt, Qualitest, Actavis, Falcon, Bausch and Lomb, and Apotex.

## History

Hi-Tech Pharmacal Co., Inc. was founded in 1982.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

## Contents

RESEARCH METHODOLOGY

DISCLAIMER

### **1. HI TECH PHARMACAL CO. INC. COMPANY PROFILE**

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

### **2. HI TECH PHARMACAL CO. INC. BUSINESS OVERVIEW**

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

### **3. HI TECH PHARMACAL CO. INC. SWOT ANALYSIS**

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

### **4. HI TECH PHARMACAL CO. INC. FINANCIAL ANALYSIS**

- 4.1. Financial Statements
  - 4.1.1. Income Statement
  - 4.1.2. Balance Sheet
  - 4.1.3. Cash Flow
- 4.2. Financial Ratios
  - 4.2.1. Profitability
  - 4.2.2. Margin Analysis

- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

## **5. HI TECH PHARMACAL CO. INC. COMPETITORS AND INDUSTRY ANALYSIS**

- 5.1. Hi Tech Pharmacal Co. Inc. Direct Competitors
- 5.2. Comparison of Hi Tech Pharmacal Co. Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of Hi Tech Pharmacal Co. Inc. and Direct Competitors Stock Charts
- 5.4. Hi Tech Pharmacal Co. Inc. Industry Analysis
  - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  - 5.4.2. Hi Tech Pharmacal Co. Inc. Industry Position Analysis

## **6. HI TECH PHARMACAL CO. INC. NEWS & EVENTS**

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

## **7. HI TECH PHARMACAL CO. INC. EXPERTS REVIEW<sup>1</sup>**

- 7.1. Experts Consensus
- 7.2. Experts Revisions

## **8. HI TECH PHARMACAL CO. INC. ENHANCED SWOT ANALYSIS<sup>2</sup>**

## **9. UNITED STATES PESTEL ANALYSIS<sup>2</sup>**

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

## **10. HI TECH PHARMACAL CO. INC. IFE, EFE, IE MATRICES<sup>2</sup>**

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

## **11. HI TECH PHARMACAL CO. INC. PORTER FIVE FORCES ANALYSIS<sup>2</sup>**

## **12. HI TECH PHARMACAL CO. INC. VRIO ANALYSIS<sup>2</sup>**

### **APPENDIX: RATIO DEFINITIONS**

### **LIST OF FIGURES**

- Hi Tech Pharmacal Co. Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
- Profit Margin Chart
- Operating Margin Chart
- Return on Equity (ROE) Chart
- Return on Assets (ROA) Chart
- Debt to Equity Chart
- Current Ratio Chart
- Hi Tech Pharmacal Co. Inc. 1-year Stock Charts
- Hi Tech Pharmacal Co. Inc. 5-year Stock Charts
- Hi Tech Pharmacal Co. Inc. vs. Main Indexes 1-year Stock Chart
- Hi Tech Pharmacal Co. Inc. vs. Direct Competitors 1-year Stock Charts
- Hi Tech Pharmacal Co. Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.  
The complete financial data is available for publicly traded companies.

## List Of Tables

### LIST OF TABLES

Hi Tech Pharmacal Co. Inc. Key Facts  
Profitability  
Management Effectiveness  
Income Statement Key Figures  
Balance Sheet Key Figures  
Cash Flow Statement Key Figures  
Financial Performance Abbreviation Guide  
Hi Tech Pharmacal Co. Inc. Key Executives  
Hi Tech Pharmacal Co. Inc. Major Shareholders  
Hi Tech Pharmacal Co. Inc. History  
Hi Tech Pharmacal Co. Inc. Products  
Revenues by Segment  
Revenues by Region  
Hi Tech Pharmacal Co. Inc. Offices and Representations  
Hi Tech Pharmacal Co. Inc. SWOT Analysis  
Yearly Income Statement Including Trends  
Income Statement Latest 4 Quarters Including Trends  
Yearly Balance Sheet Including Trends  
Balance Sheet Latest 4 Quarters Including Trends  
Yearly Cash Flow Including Trends  
Cash Flow Latest 4 Quarters Including Trends  
Hi Tech Pharmacal Co. Inc. Profitability Ratios  
Margin Analysis Ratios  
Asset Turnover Ratios  
Credit Ratios  
Long-Term Solvency Ratios  
Financial Ratios Growth Over Prior Year  
Hi Tech Pharmacal Co. Inc. Capital Market Snapshot  
Hi Tech Pharmacal Co. Inc. Direct Competitors Key Facts  
Direct Competitors Profitability Ratios  
Direct Competitors Margin Analysis Ratios  
Direct Competitors Asset Turnover Ratios  
Direct Competitors Credit Ratios  
Direct Competitors Long-Term Solvency Ratios  
Pharmaceuticals and Biotechnology Industry Statistics



Hi Tech Pharmacal Co. Inc. Industry Position  
Company vs. Industry Income Statement Analysis  
Company vs. Industry Balance Sheet Analysis  
Company vs. Industry Cash Flow Analysis  
Company vs. Industry Ratios Comparison  
Hi Tech Pharmacal Co. Inc. Consensus Recommendations<sup>1</sup>  
Analyst Recommendation Summary<sup>1</sup>  
Price Target Summary<sup>1</sup>  
Experts Recommendation Trends<sup>1</sup>  
Revenue Estimates Analysis<sup>1</sup>  
Earnings Estimates Analysis<sup>1</sup>  
Historical Surprises<sup>1</sup>  
Revenue Estimates Trend<sup>1</sup>  
Earnings Estimates Trend<sup>1</sup>  
Revenue Revisions<sup>1</sup>

## ANALYSIS FEATURES

### SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

### Enhanced SWOT Analysis

Enhanced SWOT is a 3x3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

### PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

### Key Factors Examined by PESTEL Analysis:

**Political** – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

**Economic** – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

**Sociological** – What cultural and societal aspects will work upon the demand for the business's products and operations?

**Technological** – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

**Environmental** – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

**Legal** – What laws and legislation will exert influence on the style the business is carried out?

### **IFE, EFE, IE Matrices**

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors

integrated into one suggestive model.

### **Porter Five Forces Analysis**

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

### **VRIO Analysis**

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources

Financial

Physical

Technological

Organizational

Intangible resources

Human

Innovation and Creativity

## Reputation

### Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?

Rare?

Costly to imitate?

Organized properly?

## I would like to order

Product name: Hi Tech Pharmacal Co. Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Product link: <https://marketpublishers.com/r/HF81E1094BCBEN.html>

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HF81E1094BCBEN.html>